CMAX Clinical Research

Running trials

• Recruiting

  Study Designed to Evaluate the Safety, Tolerability, and PK of RAP-219 Formulated as an Long Acting Injectable.

  NCT07923097· Phase 1· Source

• Recruiting

  A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis

  NCT07826689· Phase 1/2· Source

• Recruiting

  A Phase 1 Study of Single and Multiple Ascending Doses of GV-100

  NCT07788014· Phase 1· Source

• Recruiting

  A Study to Evaluate MWN109 Tablets in Healthy Adult Participants

  NCT06938269· Phase 1· Source

• Recruiting

  Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Followed by an Open-label Patient Cohort

  NCT06813339· Early phase 1· Source

• Active, not recruiting

  Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

  NCT06205628· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease1 recruiting
• Epilepsy1 recruiting
• Multiple sclerosis1 recruiting
• Obesity1 recruiting
• Polycystic kidney disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants

  NCT06648031· Phase 1· Source

• Completed

  Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)

  NCT06798454· Phase 1· Source

• Completed

  A Study to Investigate the Safety and Tolerability of TE-8105 in Overweight/Obese Participants Without Diabetes

  NCT06471530· Phase 1/2· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

  NCT06342713· Phase 1· Source

• Completed

  The First-in-human Study of SRN-001 in Healthy Participants

  NCT05984992· Phase 1· Source

• Completed

  Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects

  NCT05807971· Phase 1· Source

• Completed

  A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease

  NCT05792163· Phase 1· Source

• Completed

  Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-R3

  NCT05715736· Phase 1· Source

• Completed

  Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106

  NCT05054530· Phase 1· Source